Experts anticipate Daraxonrasib and new GI cancer therapies at ASCO 2026
Ahead of the 2026 ASCO Annual Meeting, leading oncologists and researchers focusing on gastrointestinal cancers highlighted the topics they expect to dominate the conference.
Central among the buzz is Daraxonrasib, a targeted agent that has shown promise in early studies, and its potential role in treating GI malignancies.
Experts also noted a broader wave of novel targeted therapies entering late-stage development, suggesting a shift toward precision medicine in the GI oncology landscape.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies”
read at onclive ↗
comments(0)
5-min edit window · permanent after that